<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02634008</url>
  </required_header>
  <id_info>
    <org_study_id>VHCRP1502</org_study_id>
    <nct_id>NCT02634008</nct_id>
  </id_info>
  <brief_title>Treatment of Recently Acquired Hepatitis C With the 3D Regimen or G/P</brief_title>
  <acronym>TARGET3D</acronym>
  <official_title>An Open Label, Multicentre, International Pilot Study of Paritaprevir/Ritonavir, Ombitasvir, Dasabuvir With or Without Ribavirin or Glecaprevir/Pibrentasvir for People With Recently Acquired Hepatitis C Virus Infection With or Without HIV Co-infection.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kirby Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>AbbVie</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Kirby Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      An open label, multicentre, international pilot study of paritaprevir/ritonavir, ombitasvir,&#xD;
      dasabuvir with or without ribavirin or glecaprevir/pibrentasvir for people with recently&#xD;
      acquired hepatitis C virus infection with or without HIV co-infection.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The use of a highly potent IFN-sparing drug combination in the setting of recently acquired 1&#xD;
      HCV infection is hypothesised to result in the vast majority of patients achieving SVR. In&#xD;
      this setting, it is anticipated that therapy can be shortened relative to that used in&#xD;
      established chronic infection. A short course IFN-free strategy is likely to be highly&#xD;
      attractive to both patients and clinicians and if proven may further encourage early HCV&#xD;
      testing and diagnosis.&#xD;
&#xD;
      In this pilot study, the investigators plan to explore the safety, efficacy and feasibility&#xD;
      of the IFN-sparing combination for treatment of recently acquired HCV infection.&#xD;
&#xD;
      Cohort One: paritaprevir/ritonavir/ombitasvir, dasabuvir with/without ribavirin (HCV genotype&#xD;
      1 only) Cohort Two (and Three): glecaprevir/pibrentasvir (HCV genotypes 1-6)&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 2016</start_date>
  <completion_date type="Anticipated">December 2024</completion_date>
  <primary_completion_date type="Actual">April 30, 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of treated subjects (intention-to-treat (ITT) population) demonstrating undetectable hepatitis C virus (HCV) RNA at 12 weeks following treatment (SVR 12).</measure>
    <time_frame>12 weeks post treatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The proportion of treated subjects overall with ETR, SVR4 and SVR24 defined as undetectable HCV RNA at end of therapy, 4 weeks and 24 weeks post therapy, respectively.</measure>
    <time_frame>End of treatment- week 6 or week 8 depending on the study arm; 4 weeks post treatment; 24 weeks post treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison of ETR, SVR4, SVR12 and SVR24 between those receiving 8 weeks treatment and those receiving 6 weeks treatment.</measure>
    <time_frame>End of treatment- week 6 or week 8 depending on the study arm; 4 weeks post treatment; 12 weeks post treatment; 24 weeks post treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison of adherence between those receiving 8 weeks treatment and those receiving 6 weeks treatment</measure>
    <time_frame>Baseline to week 6 or week 8 treatment duration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion with early treatment discontinuation</measure>
    <time_frame>Baseline through to 6 or 8 weeks depending on the study arm</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion with adverse events (including serious adverse events)</measure>
    <time_frame>Baseline to week 6 or week 8 treatment duration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in laboratory parameters, including liver function tests (ALT, AST) and haematological indices (haemoglobin, neutrophil count, platelet count)</measure>
    <time_frame>Baseline to week 6 or week 8 treatment duration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Emergence of resistance associated variants (RAVs)</measure>
    <time_frame>Baseline through to 6 or 8 weeks depending on the study arm</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HCV reinfection rate</measure>
    <time_frame>Week 208</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in sexual and injecting drug use behaviour at SVR 12 and end of follow up</measure>
    <time_frame>12 weeks post treatment; week 208</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum cytokine and ISG expression at baseline and week 4</measure>
    <time_frame>Baseline; week 4 on treatment</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Hepatitis C, Acute</condition>
  <arm_group>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Paritaprevir/ritonavir/ombitasvir (75mg/50mg/12.5mg) and dasabuvir (250mg) with or without ribavirin (1000-1200mg) daily taken orally for 8 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Three tablets of glecaprevir/pibrentasvir (100mg/40mg) daily taken orally for 6 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Three tablets of glecaprevir/pibrentasvir (100mg/40mg) daily taken orally for 4 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paritaprevir/ritonavir/ombitasvir</intervention_name>
    <arm_group_label>Cohort 1</arm_group_label>
    <other_name>Viekira Pak</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dasabuvir</intervention_name>
    <arm_group_label>Cohort 1</arm_group_label>
    <other_name>Viekira Pak</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ribavirin</intervention_name>
    <arm_group_label>Cohort 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Glecaprevir/pibrentasvir</intervention_name>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_label>Cohort 3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Provision of written informed consent;&#xD;
&#xD;
          -  Male and female patients aged 18 years and over;&#xD;
&#xD;
          -  For Cohort One: willing to use two effective methods of contraception during the&#xD;
             treatment period and 24 weeks post;&#xD;
&#xD;
          -  For Cohort Two and Three: If female and of childbearing potential, willing to use at&#xD;
             least one effective method of contraception during the treatment period and 4 weeks&#xD;
             post; women not of childbearing potential include those who are postmenopausal or&#xD;
             permanently surgically sterile (no contraception is required for male participants);&#xD;
&#xD;
          -  For Cohort One, Two and Three: Females of child-bearing potential must have a negative&#xD;
             pregnancy test at screening and immediately prior to first dose of study drugs;&#xD;
&#xD;
          -  HCV genotype 1 infection at screening (Cohort 1 only);&#xD;
&#xD;
          -  Detectable HCV RNA at screening (&gt;10,000 IU/ml), and in the opinion of the&#xD;
             investigator is unlikely to demonstrate spontaneous viral clearance;&#xD;
&#xD;
          -  Absence of cirrhosis, as defined by one of the following:&#xD;
&#xD;
               -  Liver biopsy within 24 months prior to or during screening demonstrating absence&#xD;
                  of cirrhosis (eg, METAVIR fibrosis score ≤ 3, Ishak fibrosis score ≤ 4); or&#xD;
&#xD;
               -  FibroScan score &lt; 12.5 kPa within ≤ 6 months of screening or during screening&#xD;
                  period; or&#xD;
&#xD;
          -  Medically stable on the basis of physical examination, medical history and vital&#xD;
             signs;&#xD;
&#xD;
          -  Adequate English to provide reliable responses to the study questionnaires;&#xD;
&#xD;
          -  Recently acquired HCV infection (estimated duration of infection ≤12 months) as&#xD;
             defined by*:&#xD;
&#xD;
               1. i) First anti-HCV Ab or HCV RNA positive within the previous 6 months and ii)&#xD;
                  Documented anti-HCV Ab negative within the 18 months prior to anti-HCV antibody&#xD;
                  positive result&#xD;
&#xD;
                  OR&#xD;
&#xD;
               2. i) First anti-HCV Ab or HCV RNA positive within the previous 6 months and ii)&#xD;
                  Acute clinical hepatitis (jaundice or ALT&gt; 10 X ULN) within the previous 12&#xD;
                  months prior to first positive HCV antibody or HCV RNA, with no other cause of&#xD;
                  acute hepatitis identifiable&#xD;
&#xD;
                  OR&#xD;
&#xD;
               3. i) First anti-HCV Ab or HCV RNA positive within the previous 6 months and ii)&#xD;
                  Acute asymptomatic hepatitis (acute rise in ALT&gt; 5 X ULN) within the previous 12&#xD;
                  months prior to first positive HCV antibody or HCV RNA and documented normal ALT&#xD;
                  within the previous 12 months with no othercause of acute hepatitis identifiable&#xD;
                  (In individuals with a previously high ALT, an acute rise to &gt;3.5 x their&#xD;
                  previous peak ALT in last 12 months is acceptable)&#xD;
&#xD;
                  OR&#xD;
&#xD;
               4. For cases of recent HCV reinfection the following criteria are required:&#xD;
                  Documented prior HCV antibody positive with HCV RNA negative on at least 2&#xD;
                  occasions 6 months apart AND new HCV RNA positive within the previous 6 months.&#xD;
&#xD;
                  * Estimated duration of infection based on midpoint between last antibody or RNA&#xD;
                  negative and first antibody or HCV RNA positive in the case of seroconversion and&#xD;
                  6 weeks prior to date of maximum ALT in the case of acute hepatitis.&#xD;
&#xD;
                  If co-infection with HIV is documented, the subject must meet the following&#xD;
                  criteria:&#xD;
&#xD;
                  Cohort One:&#xD;
&#xD;
          -  On a stable qualifying ARV regimen for &gt;8 weeks prior to screening visit, with CD4 T&#xD;
             cell count &gt;200 cells/mm3 and a plasma HIV RNA below the limit of detection.&#xD;
&#xD;
        Cohort Two:&#xD;
&#xD;
        • On a stable qualifying ARV regimen for &gt;8 weeks prior to screening visit, with CD4 T cell&#xD;
        count &gt;200 cells/mm3 and a plasma HIV RNA below the limit of detection.&#xD;
&#xD;
        OR&#xD;
&#xD;
        • ARV naïve with CD4 T cell count &gt;500 cells/mm3&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnancy/lactation&#xD;
&#xD;
          -  Infection or co-infection with an HCV genotype other than 1 (Cohort 1 only)&#xD;
&#xD;
          -  Subject has current or past clinical evidence of decompensated liver disease, such as&#xD;
             ascites, hepatic encephalopathy, oesophageal varices, and/or any of the following&#xD;
             screening laboratory results;&#xD;
&#xD;
               -  International Normalized Ration (INR) &gt; 1.5;&#xD;
&#xD;
               -  Patients with a known inherited blood disorder and INR &gt; 1.5 may be enrolled&#xD;
                  after discussion with the Principal Investigator&#xD;
&#xD;
               -  Serum albumin &lt;3.3 g/dL;&#xD;
&#xD;
               -  Serum total bilirubin &gt;1.8 x upper limit of normal (ULN), unless isolated in&#xD;
                  subjects with Gilbert's syndrome;&#xD;
&#xD;
          -  Subject shows evidence of significant liver disease in addition to hepatitis C, which&#xD;
             may include but is not limited to drug- or alcohol-related cirrhosis, autoimmune&#xD;
             hepatitis, hemochromatosis, Wilson's disease, non-alcoholic steatohepatitis (NASH), or&#xD;
             primary biliary cirrhosis;&#xD;
&#xD;
          -  Subject has active malignant disease or history of malignant disease within the past 5&#xD;
             years (with the exception of treated basal cell carcinoma);&#xD;
&#xD;
          -  History of chronic pulmonary disease associated with functional limitation, severe&#xD;
             cardiac disease, major organ transplantation or other evidence of severe illness,&#xD;
             malignancy, or any other conditions which would make the patient, in the opinion of&#xD;
             the investigator, unsuitable for the study;&#xD;
&#xD;
          -  Poorly controlled diabetes mellitus as evidenced by haemoglobin A1c (HbA1c) ≥8.5%;&#xD;
&#xD;
          -  Therapy with any systemic anti-viral, anti-neoplastic or immunomodulatory treatment&#xD;
             (including supraphysiologic doses of steroids and radiation) ≤6 months prior to the&#xD;
             first dose of study drug&#xD;
&#xD;
          -  Prior treatment failure with an HCV protease inhibitor;&#xD;
&#xD;
          -  Any investigational drug ≤6 weeks prior to the first dose of study drug;&#xD;
&#xD;
          -  Positive test at screening for anti-HAV IgM Ab, anti-HBc IgM Ab or HBsAg;&#xD;
&#xD;
          -  Confirmed presence of hepatocellular carcinoma indicated on imaging techniques such as&#xD;
             computed tomography (CT) scan or magnetic resonance imaging (MRI) within 3 months&#xD;
             prior to screening or on an ultrasound performed at screening (a positive ultrasound&#xD;
             result will be confirmed with CT scan or MRI);&#xD;
&#xD;
          -  Subject has history of organ transplant that requires chronic immunosuppression&#xD;
&#xD;
               -  Corneal, skin, and hair grafts are allowed;&#xD;
&#xD;
          -  History of severe psychiatric disease that in the opinion of the investigator is&#xD;
             unstable enough to compromise treatment adherence;&#xD;
&#xD;
          -  Subject has evidence of serious or severe bacterial or fungal infection(s), including&#xD;
             active tuberculosis;&#xD;
&#xD;
          -  Prohibited medications and herbal remedies as detailed in section 5.5;&#xD;
&#xD;
          -  Screening laboratory tests showing any of the following abnormal results:&#xD;
&#xD;
               -  Haemoglobin &lt;100 g/L&#xD;
&#xD;
               -  Calculated creatinine clearance &lt;50mL/min&#xD;
&#xD;
               -  Platelets &lt;100,000 cells/mm3&#xD;
&#xD;
               -  Absolute neutrophil count (ANC) &lt;1,500 cells/µL.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gail Matthews, MBBS PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Kirby Institute</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Pip Marks</last_name>
    <phone>+61 2 9385 0886</phone>
    <email>pmarks@kirby.unsw.edu.au</email>
  </overall_contact>
  <location>
    <facility>
      <name>St Vincent's Hospital</name>
      <address>
        <city>Sydney</city>
        <state>New South Wales</state>
        <zip>2010</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rebecca Hickey</last_name>
      <phone>+61 2 8382 4981</phone>
      <email>rhickey@stvincents.com.au</email>
    </contact>
    <investigator>
      <last_name>Gregory Dore, MBS PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Gail Matthews, MBBS PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Royal Adelaide Hospital</name>
      <address>
        <city>Adelaide</city>
        <state>South Australia</state>
        <zip>5000</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Catherine Ferguson</last_name>
      <phone>+61 8 8222 5635</phone>
      <email>catherine.ferguson@health.sa.gov.au</email>
    </contact>
    <investigator>
      <last_name>David Shaw</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Alfred Hospital</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3004</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michelle Hagenauer</last_name>
      <phone>03-9282 2261</phone>
      <email>gaclinresearch@alfred.org.au</email>
    </contact>
    <investigator>
      <last_name>Margaret Hellard</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Auckland City Hospital</name>
      <address>
        <city>Auckland</city>
        <state>Grafton</state>
        <zip>1023</zip>
        <country>New Zealand</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Victoria Oliver</last_name>
      <phone>+64 9 307 4949</phone>
      <phone_ext>22917</phone_ext>
      <email>VictoriaOl@adhb.govt.nz</email>
    </contact>
    <investigator>
      <last_name>Ed Gane, MD FRACP</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Christchurch Hospital</name>
      <address>
        <city>Christchurch</city>
        <zip>8011</zip>
        <country>New Zealand</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tracy Noonan</last_name>
      <phone>64 3 364 0135</phone>
      <email>Tracy.Noonan@cdhb.health.nz</email>
    </contact>
    <contact_backup>
      <last_name>Rhondda Brown</last_name>
      <phone>64 3 364 0135</phone>
      <email>Rhondda.Brown@cdhb.health.nz</email>
    </contact_backup>
    <investigator>
      <last_name>Catherine Stedman</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Barts and London</name>
      <address>
        <city>London</city>
        <zip>EC1A 7BE</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chloe Orkin, MBBCh FRCP</last_name>
      <email>chloe.orkin@bartshealth.nhs.uk</email>
    </contact>
    <investigator>
      <last_name>Chloe Orkin, MBBCh FRCP</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Royal Free Hospital</name>
      <address>
        <city>London</city>
        <zip>NW3 2QG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sanjay Bhagani, MBChB</last_name>
      <phone>+44 20 7794 0500</phone>
      <phone_ext>36285</phone_ext>
      <email>s.bhagani@nhs.net</email>
    </contact>
    <investigator>
      <last_name>Sanjay Bhagani, MBChB</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Guy's and St Thomas' Hospital</name>
      <address>
        <city>London</city>
        <zip>SE1 7EH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ranjababu Kulasegeram</last_name>
      <email>gpliaisonlbh@hcahealthcare.co.uk</email>
    </contact>
    <investigator>
      <last_name>Ranjababu Kulasegeram</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Chelsea and Westminster Hospital</name>
      <address>
        <city>London</city>
        <zip>SW10 9NH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mark Nelson, MD</last_name>
      <phone>+442087465610</phone>
      <email>m.nelson@ic.ac.uk</email>
    </contact>
    <investigator>
      <last_name>Mark Nelson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St Mary's Hospital</name>
      <address>
        <city>London</city>
        <zip>W2 1NY</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Graham Cooke</last_name>
      <email>g.cooke@imperial.ac.uk</email>
    </contact>
    <investigator>
      <last_name>Graham Cooke</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Pennine Acute Hospital</name>
      <address>
        <city>Manchester</city>
        <zip>M8 5RB</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Valerie George</last_name>
      <email>Valerie.George@pat.nhs.uk</email>
    </contact>
    <investigator>
      <last_name>Andrew Ustianowski</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>New Zealand</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>December 9, 2015</study_first_submitted>
  <study_first_submitted_qc>December 14, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 17, 2015</study_first_posted>
  <last_update_submitted>June 23, 2021</last_update_submitted>
  <last_update_submitted_qc>June 23, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 25, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pangenotypic</keyword>
  <keyword>Treatment</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Hepatitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ritonavir</mesh_term>
    <mesh_term>Ribavirin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

